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Background: Mesenchymal stem cells (MSCs) can differentiate into chondroblasts, adipocytes, or osteoblasts under
appropriate stimulation. Mechano-growth factor (MGF) reportedly displays a neuroprotective effect in cerebral
regions that were exposed to ischemia and is expressed in stromal cells of the eutopic endometrium and in
glandular cells of the ectopic endometrium.
Results: This study sought to understand the potential involvement of phosphatidylinositol-3-kinase (PI3K)/protein
kinase B (AKT) in MGF-induced growth of rabbit MSCs (rMSCs). We applied various concentrations of MGF to
cultured rMSCs and observed the growth rate of the cells, the changes in the phosphorylation state of AKT and
mammalian target of rapamycin (mTOR), and the expression levels of alkaline phosphatase and osteocalcin.
We found that the growth and osteogenic differentiation of MGF-induced rMSCs were promoted primarily by
phosphorylated AKT, and that this phosphorylation, as well mTOR phosphorylation, was mediated by the MGF
receptor.
Conclusion: Our study suggests that MGF promotes the growth and osteogenic differentiation of rMSCs primarily
through the PI3K/AKT pathway.
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Mesenchymal stem cells (MSCs) can differentiate into
chondroblasts, adipocytes, or osteoblasts under appropriate
stimulation [1]. Adult rabbit MSCs (rMSCs) are an impor-
tant source for tissue repair and therapy in regenerative
medicine [2]. Therefore, expanding the osteogenic capacity
of rMSCs is of major interest for improving the osteogenic
potential of rMSCs for optimal bone regeneration [3].
The osteogenic differentiation of MSCs is characterized
by the appearance of timely expressed genes, such as
runt-related transcription factor 2, alkaline phosphatase
(ALP) and type I collagen, followed by extracellular matrix
mineralization [4].* Correspondence: jiangdianmingtyx@163.com
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unless otherwise stated.Phosphatidylinositol-3-kinase (PI3K)/protein kinase B
(AKT) signaling pathways are activated by a variety of
extracellular stimuli and regulate a wide range of cellular
processes, including cell motility, survival, proliferation,
and cell cycle progression. Recent studies showed that
the activation of PI3K/AKT is involved in cell survival
and axonal outgrowth in neurons [5-8]. Mechano-
growth factor (MGF) has been found in many tissues. It
reportedly displays a neuroprotective effect in cerebral
regions that were exposed to ischemia and is expressed
in stromal cells of the eutopic endometrium and in
glandular cells of the ectopic endometrium. In recent
years, increasing attention has been paid to MGF be-
cause of its regenerative effects on neurons, human
mesenchymal stem cells, and osteoblasts [9,10]. In
addition, tissue-protective actions of MGF have beenhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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damage, and rabbit bone-defect models [11].
Here, we used MGF to investigate the molecular mecha-
nisms underlying MSC osteoblast differentiation and en-
hance the osteogenic potential of rabbit MSCs. Our data
revealed that MGF through PI3K/AKT signaling pathways
trigger osteogenic differentiation of rabbit bone marrow-
derived mesenchymal stromal cells.
Results
Identification of rMSCs
The morphology of the rMSCs was determined using a
microscope (Figure 1A). At day 10, cells reached 80%
confluence. At day 13, the cells displayed a uniform
spindle shape and reached 100% confluence. To further
identify the rMSCs, CD34 and CD44 cell markers were
examined. Immunofluorescence staining indicated that
the CD44 cell marker fluoresced green on the cell sur-
face under a fluorescent microscope, whereas CD34
fluoresced brown (not green), indicating that culturedFigure 1 Identification of rMSCs. (A) Morphology of rMSCs at 0, 8, and 1
expression of CD34 and CD44 in cultured rBMSCs. (C) Cellular proliferation
absorbance of 570 nm).cells were positive for CD44, but negative for CD34
(Figure 1B).
The proliferation of the cells for the second through
the fifth cell passages was analyzed with an automated
microplate reader at an absorbance of 570 nm on days
1–10. As shown in Figure 1C, the growth curves for the
passaged cells displayed “S” shapes, with the latent
growth phase of the passaged cells stabilizing during the
first to second days. The cells from the fourth and fifth
passages were 100% confluent at 7 days and then en-
tered a lag phase. However, the cells from the second
and third passages entered the lag phase 2 days later.
Thus, the cells from the fourth passage displayed the
greatest ability to proliferate (P < 0.05).
MGF receptor expression in rMSCs
To detect the expression of MGF receptor in rMSCs,
we used immunocytochemistry techniques, and Figure 2
shows MGF receptors expressed in rMSCs. MGF ex-
pressed in the cytoplasm.5 days of culture. (B) Immunofluorescence staining showing the
during the second through fifth cell passages (as determined at an
Figure 2 Mechano-growth factor (MGF) receptors expressed in
cultured rBMSCs.
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MGF-induced effects on rMSCs
The optimal MGF concentration and application time for
the MGF-induced effects on the rMSCs were determined.
Figure 3 shows the growth rates of rMSCs from the fourth
cell passage for 1–10 days following the addition to the
cell culture media of 15, 30, 45, 60, or 75 ng/ml of MGF.
The maximum growth rate appeared at an MGF concen-
tration of 45 nM between days 4 and 5.Figure 3 Growth rates of cultured rMSCs treated for 1–10 days with MMGF promotes the growth and differentiation of rMSCs
via the PI3K/AKT pathway
To identify the signaling pathway through which MGF
acts on rMSCs, cells were treated with 45 nM of MGF for
5 days (the optimal conditions as determined above), and
the phosphorylation states of AKT and mTOR were exa-
mined at 0, 4, 8, 12, and 16 h following treatment on day 5
(Figure 4A). Figure 4B shows that the phosphorylation of
AKT and mTOR increased. To further explore the func-
tion of MGF, the expression levels of ALP and OCN were
examined in the osteoblasts that were formed from the
rMSCs. The expression of these two proteins was higher
at 4 h that at other time in cells treated with 45 nM MGF
for 4 h on the fifth day of treatment (Figure 5).
To verify that MGF promotes the growth and differen-
tiation of rMSCs via the PI3K/AKT pathway, the PI3K/
AKT inhibitor LY294002 with 20 μmol/L was used to
inhibit PI3K/AKT activity (Figure 6A). Following the
addition of LY294002, the cells were treated with MGF
for 1–10 days, and their growth rates were compared
with those of cells that did not receive LY294002 treat-
ment (Figure 6B). We found that the phosphorylation of
mTOR was decreased compared with that of controls
(Figure 6A). The inhibition of PI3K/AKT also blocked
the ability of MGF at 45 nM to increase the growth rate
of rMSCs, even after 10 days of treatment. In addition,
the expression levels of ALP and OCN were decreased
compared with those in control osteoblasts (Figure 7).
Discussion
Finding mechanisms that trigger the growth and osteo-
genic differentiation of rMSCs may help develop novel
therapeutic approaches to promote bone formation [12].
In the present study, we demonstrated that MGF pro-
moted the growth rate and osteogenic differentiation of
rMSCs via the PI3K/AKT pathway.
The identity of rMSCs were verified by their mor-
phology and the finding that the rMSCs expressed
CD44, a marker of rMSCs, but not CD34, a closelyGF (15, 30, 45, 60, or 75 ng/ml).
Figure 4 Effects of MGF (45 nM) on the phosphorylation of AKT
and mTOR at 0, 4, 8, 12, and 16 h on the 5th day of MGF
treatment. (A) The expression levels of AKT, mTOR, phospho-AKT, and
phospho-mTOR. (B) Contrast gray values for the phosphorylation of
AKT and mTOR (*P < 0.05).
Figure 6 Effects of LY294002 on the PI3K/AKT pathway and
growth rates of rBMSCs. (A) The protein expression levels of AKT
and mTOR and phosphorylated AKT and phosphorylated mTOR
following the addition of the PI3K/AKT inhibitor LY294002. (B)
Effects of LY294002 on the growth rates of rMSCs treated with MGF
(45 ng/ml) for 1–10 days.
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proliferation following the second through fifth passages
was analyzed on days 1–10 following the passages. The
fourth generation rMSCs showed the greatest capacity
for proliferation, whereas the second generation showed
the weakest.
We determined that the maximum growth rate of
rMSCs was achieved by the addition of 45 nM MGF to
the culture medium for 5 days. We also demonstrated
that the MGF receptor is expressed at high levels in
rMSCs.
To gain further insight into the mechanisms through
which MGF promotes growth and differentiation in
rMSCs, we evaluated the activity of the signaling path-
ways downstream of the MGF receptor. The PI3K/
AKT/mTOR signaling pathway plays a crucial role inFigure 5 Expression of ALP and OCN protein levels in 0, 4, 8,
12 and 16 h.
Figure 7 Effects of LY294002 on the expression of ALP and
OCN protein levels.
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angiogenesis, metabolism, differentiation, and survival
[13]. The results of our present study suggested that MGF
promoted the growth of rMSCs via the PI3K/AKT signal-
ing pathway. We found that 4 h on the fifth day of MGF
treatment was required to stimulate maximal phosphoryl-
ation of AKT and mTOR and maximal expression of ALP
and OCN. Furthermore, inhibiting AKT with LY294002
suppressed the MGF-mediated promotion of growth and
osteogenic differentiation in rMSCs.
Conclusion
Overall, our study suggests that the MGF receptor sig-
naling pathway accelerates growth in rMSCs primarily
through a PI3K/AKT-dependent pathway. Despite this
promising finding, further study is necessary before any
clinical applications can be considered.
Methods
Unless otherwise specified, all chemicals and reagents
were purchased from the Sigma Chemical Company (St.
Louis, MO, USA). MGF was purchased from Chemicon
International (Temecula, CA, USA). Antibodies to IgG,
β-actin, AKT, mammalian target of rapamycin (mTOR),
ALP, osteocalcin (OCN), CD44, CD34, MGF receptor,
phospho-AKT, phospho-mTOR, and phospho-p90RSK1
(Ser380) were purchased from the Millipore Corpor-
ation, USA.
Isolation and culture of rMSCs
The femur from a neonatal New Zealand white rabbit
was isolated, and the ends of the femur were opened.
The bone marrow was flushed from the femur with low
glucose Dulbecco’s modified Eagle’s medium (DMEM)
using a 1 mL syringe. Cells were harvested in a culture
dish, dissolved using a Pasteur pipette, seeded onto a
flask containing DMEM and 15% fetal bovine serum,
and cultured in an incubator with 5% CO2 at 37°C. The
medium was replaced every 2 days. When cells grew to
a confluence of approximately 85%, they were passaged
with 0.25% trypsin and 0.1% EDTA (1:2). Cell growth
was monitored under an inverted phase contrast micro-
scope (Nikon Co.). The animal test was agreed by The




Cells were grown in 96-well plates (1 × 103 cells/well)
supplement with MGF. Control cells were switched from
RPMI-1640 to DMEM containing 0.1% dimethyl sulfox-
ide (DMSO). At 1, 2,3, 45,6,7,8 and 9 days following
MGF treatment (0, 15, 30, 45, 60 and 75 nM MGF),
20 μL of MTT was added to each well to a finalconcentration of 0.5%. After a 4 h incubation at 37°C in
the dark, 150 μL DMSO was added to each well for
10 min to dissolve the formazan crystals. The absorb-
ance was measured using a microplate reader (EXL800,
Cole-Parmer, Vernon Hills, IL, USA) at 490 nm. All ex-
periments were repeated three times. The viability of the
MGF treated cells was expressed as percentage of po-
pulation growth plus the standard error of the mean
(SEM) relative to that of untransfected control cells. Cell
growth was calculated as follows: % growth = (mean ex-
perimental absorbance- mean control absorbance/mean
control absorbance) × 100.
Immunofluorescence
The rMSCs were fixed in 3.7% paraformaldehyde for
30 min at room temperature, permeabilized with 0.5%
Triton X-100 in PBS for 15 min, and blocked with 1%
BSA in phosphate buffered saline (PBS) with 10% goat
serum overnight at 4°C. The samples were then stained
with primary antibodies diluted in PBS. The primary
antibody binding was detected with an Alexa Fluor 488
Goat anti-rabbit IgG (H + L) secondary antibody. Images
were captured with a Nikon A1 confocal microscope.
Experiments were performed in triplicate.
Immunohistochemistry
Immunohistochemistry was performed as follows: cell
sections were three times for 1 min in phosphate buff-
ered saline (PBS), once fixed for 15 min in ice acetone,
three times for 2 min in PBS, 0.5% Triton X-100 20 min.
Antigens were recovered by heating the sections in a
microwave oven for 15 min, after which the sections
were washed three times for 5 min with PBS. Endogen-
ous peroxidase activity was blocked by soaking the slides
in a solution of 3% hydrogen peroxide for 15 min at
room temperature (RT), followed by washing three times
for 5 min with PBS. Non-immune Goat blood serum
(50 μL) was added to each section for 15 min at RT,
followed by the primary antibodies (Millipore, 50 μL).
Slides were incubated overnight at 4°C in a humidified
chamber and washed three times for 10 min in PBS.
Biotin-labeled secondary antibodies (50 μL) were added
to each section and kept for 15 min at 37°C, followed by
washing three times for 5 min with PBS. Samples were
incubated for 15 min at RT and washed three times for
5 min in PBS before the addition of 100 L freshly pre-
pared 3,3-diaminobenzidine (DAB) for approximately 5–
20 min. The reaction was stopped by washing in cold
water. Slides were counterstained with hematoxylin,
followed by a sealing procedure using neural gum.
Western blot
The protein homogenates from human neurons were sep-
arated using electrophoresis on 8-12% sodium dodecyl
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blot nitrocellulose membranes. Membranes were blocked
for 30 min at room temperature in PBS buffer containing
5% fat-free milk and 0.1% Tween 20. Membranes were
then incubated with primary antibody for at least 1 h at
room temperature or overnight at 4°C. The membranes
were subsequently washed three times with PBS contain-
ing 0.1% Tween 20, incubated with peroxidase-conjugated
secondary antibodies, and developed using ECL reagents
(Pierce, Rockford, IL, USA).
Osteogenic differentiation
The rMSCs were plated at a density of 5000 cells/cm2
and exposed to standard differentiation-inducing media
for 21 days. The medium was changed twice per week.
Osteogenic differentiation was achieved following stan-
dard in vitro protocols. Endothelial differentiation was
stimulated by culturing the cells in Endothelial Growth
Medium-2 (EGM-2).
Statistical analysis
Statistically significant differences between gene expression
levels were determined using one-way analysis of variance
(ANOVA) followed by a Newman–Keuls test with Graph-
Pad Prism version 5 software (GraphPad Software, La Jolla,
CA, USA, www.graphpad.com/company/). Replicates were
included in the statistical model. Differences were consi-
dered statistically significant at the 95% confidence level
(P < 0.05). Data are presented as mean ± S.D.
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